Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Nonmicrobicidal Small Molecule Inhibition of Polysaccharide Metabolism in Human Gut Microbes: A Potential Therapeutic Avenue.

Santilli AD, Dawson EM, Whitehead KJ, Whitehead DC.

ACS Chem Biol. 2018 Apr 20. doi: 10.1021/acschembio.8b00309. [Epub ahead of print]

PMID:
29660284
2.

Clinical presentation and treatment paradigms of brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.

Gamboa NT, Joyce EJ, Eli I, Park MS, Taussky P, Schmidt RH, McDonald J, Whitehead KJ, Kalani MYS.

J Clin Neurosci. 2018 May;51:22-28. doi: 10.1016/j.jocn.2018.01.019. Epub 2018 Feb 23.

PMID:
29483005
3.

Clinical presentation and treatment paradigms in patients with hereditary hemorrhagic telangiectasia and spinal vascular malformations.

Eli I, Gamboa NT, Joyce EJ, Park MS, Taussky P, Schmidt RH, Couldwell WT, McDonald J, Whitehead KJ, Kalani MYS.

J Clin Neurosci. 2018 Apr;50:51-57. doi: 10.1016/j.jocn.2018.01.010. Epub 2018 Feb 3.

PMID:
29398197
4.

Epistaxis in children and adolescents with hereditary hemorrhagic telangiectasia.

Gonzalez CD, Mcdonald J, Stevenson DA, Whitehead KJ, Petersen MG, Presson AP, Ding Q, Wilson KF.

Laryngoscope. 2017 Nov 24. doi: 10.1002/lary.27015. [Epub ahead of print]

PMID:
29171658
5.

Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Girard R, Zeineddine HA, Fam MD, Mayampurath A, Cao Y, Shi C, Shenkar R, Polster SP, Jesselson M, Duggan R, Mikati AG, Christoforidis G, Andrade J, Whitehead KJ, Li DY, Awad IA.

Transl Stroke Res. 2018 Feb;9(1):34-43. doi: 10.1007/s12975-017-0561-3. Epub 2017 Aug 17.

PMID:
28819935
6.

Endothelial TLR4 and the microbiome drive cerebral cavernous malformations.

Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA, Lightle R, Moore T, Cao Y, Shenkar R, Chen M, Mericko P, Yang J, Li L, Tanes C, Kobuley D, Võsa U, Whitehead KJ, Li DY, Franke L, Hart B, Schwaninger M, Henao-Mejia J, Morrison L, Kim H, Awad IA, Zheng X, Kahn ML.

Nature. 2017 May 18;545(7654):305-310. doi: 10.1038/nature22075. Epub 2017 May 10.

7.

Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR.

JAMA. 2016 Sep 6;316(9):943-51. doi: 10.1001/jama.2016.11724.

PMID:
27599329
8.

Corrigendum: Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML.

Nature. 2016 Aug 25;536(7617):488. doi: 10.1038/nature18311. Epub 2016 May 25. No abstract available.

PMID:
27281211
9.

Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, Arthur JS, Whitehead KJ, Awad IA, Li DY, Zheng X, Kahn ML.

Nature. 2016 Apr 7;532(7597):122-6. doi: 10.1038/nature17178. Epub 2016 Mar 30. Erratum in: Nature. 2016 May 25;536(7617):488.

10.

Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.

Girard R, Khanna O, Shenkar R, Zhang L, Wu M, Jesselson M, Zeineddine HA, Gangal A, Fam MD, Gibson CC, Whitehead KJ, Li DY, Liao JK, Shi C, Awad IA.

Biomark Med. 2016;10(3):255-64. doi: 10.2217/bmm.15.118. Epub 2016 Feb 9.

11.

Small GTPase Rap1 Is Essential for Mouse Development and Formation of Functional Vasculature.

Chrzanowska-Wodnicka M, White GC 2nd, Quilliam LA, Whitehead KJ.

PLoS One. 2015 Dec 29;10(12):e0145689. doi: 10.1371/journal.pone.0145689. eCollection 2015.

12.

Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.

Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J, Gerdes AM, Jönsson G, Hayward NK.

Oncotarget. 2016 Jan 26;7(4):4624-31. doi: 10.18632/oncotarget.6614.

13.

An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2.

Hunter BN, Timmins BH, McDonald J, Whitehead KJ, Ward PD, Wilson KF.

Laryngoscope. 2016 Apr;126(4):786-90. doi: 10.1002/lary.25604. Epub 2015 Sep 15.

14.

The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression.

Zhou Z, Rawnsley DR, Goddard LM, Pan W, Cao XJ, Jakus Z, Zheng H, Yang J, Arthur JS, Whitehead KJ, Li D, Zhou B, Garcia BA, Zheng X, Kahn ML.

Dev Cell. 2015 Jan 26;32(2):168-80. doi: 10.1016/j.devcel.2014.12.009.

15.

Brain arteriovenous malformations.

Lawton MT, Rutledge WC, Kim H, Stapf C, Whitehead KJ, Li DY, Krings T, terBrugge K, Kondziolka D, Morgan MK, Moon K, Spetzler RF.

Nat Rev Dis Primers. 2015 May 28;1:15008. doi: 10.1038/nrdp.2015.8. Review.

PMID:
27188382
16.

Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, Shiu YT, Grossmann AH, Thomas KR, Donato AJ, Lesniewski LA, Whitehead KJ, Li DY.

Circulation. 2015 Jan 20;131(3):289-99. doi: 10.1161/CIRCULATIONAHA.114.010403. Epub 2014 Dec 8.

17.

Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy.

Kannan S, Muthusamy VR, Whitehead KJ, Wang L, Gomes AV, Litwin SE, Kensler TW, Abel ED, Hoidal JR, Rajasekaran NS.

Cardiovasc Res. 2013 Oct 1;100(1):63-73. doi: 10.1093/cvr/cvt150. Epub 2013 Jun 12.

18.

Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth.

Zhu Y, Pires KM, Whitehead KJ, Olsen CD, Wayment B, Zhang YC, Bugger H, Ilkun O, Litwin SE, Thomas G, Kozma SC, Abel ED.

PLoS One. 2013;8(1):e54221. doi: 10.1371/journal.pone.0054221. Epub 2013 Jan 14.

19.

Arteriovenous malformations and other vascular malformation syndromes.

Whitehead KJ, Smith MC, Li DY.

Cold Spring Harb Perspect Med. 2013 Feb 1;3(2):a006635. doi: 10.1101/cshperspect.a006635. Review.

20.

Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training.

Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KJ, Odelberg SJ, Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS.

PLoS One. 2012;7(9):e45697. doi: 10.1371/journal.pone.0045697. Epub 2012 Sep 24. Erratum in: PLoS One. 2013;8(6). doi: 10.1371/annotation/684807c2-1777-4008-9eda-c6036553b082. PLoS One. 2012;7(10). doi:10.1371/annotation/8690bb36-3c5d-48a6-b3be-39a2b50896e1. Whitehead, Kevin S [corrected to Whitehead, Kevin J].

21.

Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Chan AC, Drakos SG, Ruiz OE, Smith AC, Gibson CC, Ling J, Passi SF, Stratman AN, Sacharidou A, Revelo MP, Grossmann AH, Diakos NA, Davis GE, Metzstein MM, Whitehead KJ, Li DY.

J Clin Invest. 2011 May;121(5):1871-81. doi: 10.1172/JCI44393. Epub 2011 Apr 1. Erratum in: J Clin Invest. 2012 May 1;122(5):1948.

22.

Evaluating strategies for the treatment of cerebral cavernous malformations.

Li DY, Whitehead KJ.

Stroke. 2010 Oct;41(10 Suppl):S92-4. doi: 10.1161/STROKEAHA.110.594929. Review.

23.

The pathogenetic features of cerebral cavernous malformations: a comprehensive review with therapeutic implications.

Krisht KM, Whitehead KJ, Niazi T, Couldwell WT.

Neurosurg Focus. 2010 Sep;29(3):E2. doi: 10.3171/2010.6.FOCUS10135. Review.

PMID:
20809760
24.

Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart.

Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, Whitehead KJ, Salama ME, Selzman CH, Stehlik J, Clayson SE, Bristow MR, Renlund DG, Li DY.

J Am Coll Cardiol. 2010 Jul 27;56(5):382-91. doi: 10.1016/j.jacc.2010.04.019.

25.

Reply to a letter to editor "Nickel allergy, Amplatzer atrial septal occluder device, and the risk of Kounis syndrome".

Michaels AD, Powell DL, Whitehead KJ.

Clin Cardiol. 2010 Apr;33(4):E61. doi: 10.1002/clc.20743. No abstract available.

26.

Mechanisms of vascular stability and the relationship to human disease.

Smith MC, Li DY, Whitehead KJ.

Curr Opin Hematol. 2010 May;17(3):237-44. doi: 10.1097/MOH.0b013e3283386750. Review.

27.

Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype.

Chan AC, Li DY, Berg MJ, Whitehead KJ.

FEBS J. 2010 Mar;277(5):1076-83. doi: 10.1111/j.1742-4658.2009.07536.x. Epub 2010 Jan 22. Review.

28.

Dynamic regulation of spinal pro-inflammatory cytokine release in the rat in vivo following peripheral nerve injury.

Whitehead KJ, Smith CG, Delaney SA, Curnow SJ, Salmon M, Hughes JP, Chessell IP.

Brain Behav Immun. 2010 May;24(4):569-76. doi: 10.1016/j.bbi.2009.12.007. Epub 2009 Dec 24.

PMID:
20035858
29.

Unusual presentation of nickel allergy requiring explantation of an Amplatzer atrial septal occluder device.

Rabkin DG, Whitehead KJ, Michaels AD, Powell DL, Karwande SV.

Clin Cardiol. 2009 Aug;32(8):E55-7. doi: 10.1002/clc.20427.

30.

Endogenous endothelial cell signaling systems maintain vascular stability.

London NR, Whitehead KJ, Li DY.

Angiogenesis. 2009;12(2):149-58. doi: 10.1007/s10456-009-9130-z. Epub 2009 Jan 27. Review.

31.

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases.

Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, Mayo AH, Drakos SG, Jones CA, Zhu W, Marchuk DA, Davis GE, Li DY.

Nat Med. 2009 Feb;15(2):177-84. doi: 10.1038/nm.1911. Epub 2009 Jan 18. Erratum in: Nat Med. 2009 Apr;15(4):462. Jones, Christopher A [added]; Zhu, Weiquan [added].

32.

The netrin receptor UNC5B promotes angiogenesis in specific vascular beds.

Navankasattusas S, Whitehead KJ, Suli A, Sorensen LK, Lim AH, Zhao J, Park KW, Wythe JD, Thomas KR, Chien CB, Li DY.

Development. 2008 Feb;135(4):659-67. doi: 10.1242/dev.013623.

33.
34.

Monolithic column-based reversed-phase liquid chromatography separation for amino acid assay in microdialysates and cerebral spinal fluid.

Devall AJ, Blake R, Langman N, Smith CG, Richards DA, Whitehead KJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):323-8. Epub 2006 Nov 13.

PMID:
17101306
35.

Eosinophilic angiocentric fibrosis: an unusual entity producing complete lacrimal duct obstruction.

Valenzuela AA, Whitehead KJ, Brown I, Sullivan TJ.

Orbit. 2006 Jun;25(2):159-61.

PMID:
16754230
36.

Ocular adnexal pseudo-cyst formation as a characteristic feature of perineural spread in squamous cell carcinoma.

Valenzuela AA, Whitehead KJ, Sullivan TJ.

Ophthal Plast Reconstr Surg. 2006 May-Jun;22(3):201-5.

PMID:
16714930
37.

Adrenaline increases carotid body CO2 sensitivity: an in vivo study.

Maskell PD, Rusius CJ, Whitehead KJ, Kumar P.

Adv Exp Med Biol. 2006;580:245-50; discussion 351-9. No abstract available.

PMID:
16683727
38.

Clinical features and management of tumors affecting the lacrimal drainage apparatus.

Valenzuela AA, McNab AA, Selva D, O'Donnell BA, Whitehead KJ, Sullivan TJ.

Ophthal Plast Reconstr Surg. 2006 Mar-Apr;22(2):96-101.

PMID:
16550051
39.

Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo.

Langman NJ, Smith CG, Whitehead KJ.

Pharmacol Res. 2006 Feb;53(2):149-55. Epub 2005 Nov 8.

PMID:
16280247
40.

Positive N-methyl-D-aspartate receptor modulation by selective glycine transporter-1 inhibition in the rat dorsal spinal cord in vivo.

Whitehead KJ, Pearce SM, Walker G, Sundaram H, Hill D, Bowery NG.

Neuroscience. 2004;126(2):381-90.

PMID:
15207356
41.
42.

Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations.

Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY.

Development. 2004 Mar;131(6):1437-48.

43.

The management of perineural spread of squamous cell carcinoma to the ocular adnexae.

Bowyer JD, Sullivan TJ, Whitehead KJ, Kelly LE, Allison RW.

Ophthal Plast Reconstr Surg. 2003 Jul;19(4):275-81.

PMID:
12878875
44.

Periocular keratoacanthoma: clinical features, pathology, and management.

Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM.

Ophthalmology. 2003 Jul;110(7):1403-7.

PMID:
12867399
45.

Dirofilarial infection of the orbit.

Angunawela RI, Ataullah S, Whitehead KJ, Sullivan TJ, Rosser P.

Orbit. 2003 Mar;22(1):41-6.

PMID:
12759866
46.

Management of periocular basal cell carcinoma with modified en face frozen section controlled excision.

Wong VA, Marshall JA, Whitehead KJ, Williamson RM, Sullivan TJ.

Ophthal Plast Reconstr Surg. 2002 Nov;18(6):430-5.

PMID:
12439056
47.

Squamous cell carcinoma of the eyelids.

Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM.

Br J Ophthalmol. 2002 Oct;86(10):1161-5.

48.

Intraepidermal carcinoma of the eyelid.

Sullivan TJ, Boulton JE, Whitehead KJ.

Clin Exp Ophthalmol. 2002 Feb;30(1):23-7.

PMID:
11885790
50.

Eccrine poroma of the eyelid.

Vu PP, Whitehead KJ, Sullivan TJ.

Clin Exp Ophthalmol. 2001 Aug;29(4):253-5.

PMID:
11545426

Supplemental Content

Loading ...
Support Center